@article{nokey,

title = {Stem cell therapy for COVID-19 pneumonia},

author = {Maziar Malekzadeh Kebria and Peiman Brouki Milan and Noshad Peyravian and Jafar Kiani and Soheil Khatibi and Masoud Mozafari},

url = {https://doi.org/10.1186/s43556-021-00067-8},

year  = {2022},

date = {2022-02-17},

abstract = {Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus is a highly contagious microorganism, and despite substantial investigation, no progress has been achieved in treating post-COVID complications. However, the virus has made various mutations and has spread around the world. Researchers have tried different treatments to reduce the side effects of the COVID-19 symptoms. One of the most common and effective treatments now used is steroid therapy to reduce the complications of this disease. Long-term steroid therapy for chronic inflammation following COVID-19 is harmful and increases the risk of secondary infection, and effective treatment remains challenging owing to fibrosis and severe inflammation and infection. Sometimes our immune system can severely damage ourselves in disease. In the past, many researchers have conducted various studies on the immunomodulatory properties of stem cells. This property of stem cells led them to modulate the immune system of autoimmune diseases like diabetes, multiple sclerosis, and Parkinson's. Because of their immunomodulatory properties, stem cell-based therapy employing mesenchymal or hematopoietic stem cells may be a viable alternative treatment option in some patients. By priming the immune system and providing cytokines, chemokines, and growth factors, stem cells can be employed to build a long-term regenerative and protective response. This review addresses the latest trends and rapid progress in stem cell treatment for Acute Respiratory Distress Syndrome (ARDS) following COVID-19.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Human mesenchymal stem cells treatment for severe COVID-19},

author = {Lei Shi and Xin Yuan and Weiqi Yao and Siyu Wang and Chao Zhang and Bo Zhang and Jinwen Song and Lei Huang and Zhe Xu},

url = {https://doi.org/10.1016/j.ebiom.2021.103789},

year  = {2021},

date = {2021-12-25},

abstract = {MSC administration improved in whole-lung lesion volume compared with the placebo with a difference of -10.8% (95% CI: -20.7%, -1.5%, p = 0.030) on day 10. MSC also reduced the proportion of solid component lesion volume compared with the placebo at each follow-up point. More interestingly, 17.9% (10/56) of patients in the MSC group had normal CT images at month 12, but none in the placebo group (p = 0.013). The incidence of symptoms was lower in the MSC group than in the placebo group at each follow-up time. Neutralizing antibodies were all positive, with a similar median inhibition rate (61.6% vs. 67.6%) in both groups at month 12. No difference in adverse events at the 1-year follow-up and tumor markers at month 12 were observed between the two groups.

},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Potential for Stem Cell-Based Therapy in the Road of Treatment for Neurological Disorders Secondary to COVID-19},

author = {Babak Arjmand and Peyvand Parhizkar Roudsari and Sepideh Alavi-Moghadam and Mostafa Rezaei-Tavirani and Akram Tayanloo-Beik and Neda Mehrdad and Hossein Adibi and Bagher Larijani},

url = {https://doi.org/10.1007/s40883-021-00234-x},

year  = {2021},

date = {2021-10-29},

urldate = {2021-10-29},

abstract = {Due to the substantial burden of neurological disorders in the health, economic, and social system of society, the emergence of neurological manifestations following COVID-19 (as a life-threatening pandemic) creates the need to use efficient and modern methods of treatment. Since stem cell-based methods have been efficient for a large number of neurological diseases, it seems that the use of mentioned methods is also effective in the process of improving neurological disorders caused by COVID-19. Hereupon, the current review aims to address stem cell-based approaches as treatments showing promise to neurological disorders related to COVID-19.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}